Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Chemical Works of Gedeon Richter EV-to-OCF?
Chemical Works of Gedeon RichterRGEDF +3.40%97 EV-to-OCF is 15.67 as of Aug. 11, 2026, which is 52% above its 10-year median of 10.28. GuruFocus rates RGEDF with a GF Score™ of 97/100 and a GF Value™ of $36.36 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Chemical Works of Gedeon Richter ranks worse than 63.62% on this metric.
The historical rank and industry rank for Chemical Works of Gedeon Richter's EV-to-OCF or its related term are showing as below:
RGEDF'
s EV-to-OCF Range Over the Past 10 Years
Min: 6.81 Med: 10.28 Max: 16.86
Current: 15.67
During the past 13 years, the highest EV-to-OCF of Chemical Works of Gedeon Richter was 16.86. The lowest was 6.81. And the median was 10.28.
RGEDF's EV-to-OCF is ranked worse than 63.62% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 11.055
vs RGEDF: 15.67
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Chemical Works of Gedeon Richter (OTCPK:RGEDF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Chemical Works of Gedeon Richter's PE Ratio (TTM) for today is calculated as:
Chemical Works of Gedeon Richter's share price for today is $41.4938.
Chemical Works of Gedeon Richter's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.791.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Chemical Works of Gedeon Richter EV-to-OCF Related Terms
Chemical Works of Gedeon Richter EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Chemical Works of Gedeon Richter's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemical Works of Gedeon Richter EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chemical Works of Gedeon Richter's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Chemical Works of Gedeon Richter's EV-to-OCF falls into.
Chemical Works of Gedeon Richter's current Enterprise Value is $6,806 Mil.
Chemical Works of Gedeon Richter's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $434 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemical Works of Gedeon Richter (RGEDF) has a EV-to-OCF of 15.67 as of Aug. 11, 2026. This is 52% above median its historical median of 10.28. Over the past decade, Chemical Works of Gedeon Richter's EV-to-OCF has ranged from 6.81 to 16.86. According to the industry distribution chart, Chemical Works of Gedeon Richter ranks #640 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 63.6%.
Is Chemical Works of Gedeon Richter's EV-to-OCF too high?
Chemical Works of Gedeon Richter's current EV-to-OCF of 15.67 is 52% above median its 10-year median of 10.28. Over the past 10 years, this metric has ranged from a low of 6.81 to a high of 16.86. The Drug Manufacturers industry median EV-to-OCF is 11.06. Chemical Works of Gedeon Richter's value of 15.67 is 41.7% above this industry median. Based on the distribution chart, Chemical Works of Gedeon Richter ranks #640 out of 1006 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Chemical Works of Gedeon Richter has a GF Score™ of 97/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chemical Works of Gedeon Richter's EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Chemical Works of Gedeon Richter ranks #640 out of 1006 companies for EV-to-OCF. This places Chemical Works of Gedeon Richter in the lower half of its industry. The industry median EV-to-OCF is 11.06. Chemical Works of Gedeon Richter's value of 15.67 is 41.7% above this benchmark. Historically, Chemical Works of Gedeon Richter's own EV-to-OCF has ranged from 6.81 to 16.86 over the past decade. While the company's 10-year median is 10.28 vs. the industry median of 11.06, Chemical Works of Gedeon Richter has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.06, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chemical Works of Gedeon Richter's current EV-to-OCF of 15.67 is 41.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemical Works of Gedeon Richter's current EV-to-OCF is 15.67, which is 52% above median its own 10-year median of 10.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemical Works of Gedeon Richter stock overvalued right now?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter (RGEDF) is currently considered Modestly Overvalued. The stock's GF Value™ is $36.36, compared to a current price of $41.49 — trading 14.1% above its estimated fair value. The current EV-to-OCF is 15.67, which is 52% above median its 10-year median of 10.28 and 41.7% above the Drug Manufacturers industry median of 11.06. Chemical Works of Gedeon Richter's overall GF Score™ is 97/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Chemical Works of Gedeon Richter (RGEDF), the current EV-to-OCF is 15.67 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chemical Works of Gedeon Richter (RGEDF) Overvalued in 2026?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter stock appears to be overvalued.
The current stock price of $41.49 is trading 14.1% above its estimated GF Value™ of $36.36.
GuruFocus considers Chemical Works of Gedeon Richter to be Modestly Overvalued.
Key valuation signals for RGEDF:
EV-to-OCF: 15.67 (52% above median its 10-year median of 10.28)
GF Value™: $36.36 vs. price of $41.49 (14.1% above fair value)
Industry Position: 41.7% above the Drug Manufacturers median (#640 of 1006)
No single metric tells the full story. See the RGEDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chemical Works of Gedeon Richter PLC is a pharmaceutical company. The company focuses on the development and manufacture of gynaecological, cardiovascular, and central nervous system products. It manufactures medicines including original, generic and licensed products for treatment in the therapeutic area. The group is active in two business segments namely, the Pharma segment comprising Women's Healthcare, Neuropsychiatry, Biotechnology, General Medicine, and Other pharma; and the Others segment includes the remaining wholesale and retail business of the Group and all other activities. The company operates internationally.
97GF Score
Get the complete analysis for RGEDF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGEDF has been successfully added to your 
